학술논문
Burosumab, a Fully Human Anti-FGF23 Monoclonal Antibody, for X-Linked Hypophosphatemia (XLH): Sustained Improvement in Two Phase 2 Trials in Affected Children 1-12 Years Old
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
16632826